Reviewing GSK (NYSE:GSK) & Verrica Pharmaceuticals (NASDAQ:VRCA)

Verrica Pharmaceuticals (NASDAQ:VRCA – Get Free Report) and GSK (NYSE:GSK – Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, profitability, valuation, risk, dividends and analyst recommendations.

Insider & Institutional Ownership

42.5% of Verrica Pharmaceuticals shares are owned by institutional investors. Comparatively, 15.7% of GSK shares are owned by institutional investors. 52.9% of Verrica Pharmaceuticals shares are owned by company insiders. Comparatively, 10.0% of GSK shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Verrica Pharmaceuticals and GSK’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Verrica Pharmaceuticals -189.23% -423.63% -102.46%
GSK 13.00% 41.41% 11.09%

Valuation & Earnings

This table compares Verrica Pharmaceuticals and GSK”s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Verrica Pharmaceuticals $35.58 million 1.52 -$17.89 million ($2.22) -1.41
GSK $43.07 billion 2.31 $7.54 billion $2.88 17.10

GSK has higher revenue and earnings than Verrica Pharmaceuticals. Verrica Pharmaceuticals is trading at a lower price-to-earnings ratio than GSK, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Verrica Pharmaceuticals has a beta of 1.69, indicating that its share price is 69% more volatile than the S&P 500. Comparatively, GSK has a beta of 0.29, indicating that its share price is 71% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current recommendations for Verrica Pharmaceuticals and GSK, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Verrica Pharmaceuticals 1 1 3 0 2.40
GSK 3 13 3 0 2.00

Verrica Pharmaceuticals presently has a consensus price target of $12.67, indicating a potential upside of 303.40%. GSK has a consensus price target of $56.30, indicating a potential upside of 14.30%. Given Verrica Pharmaceuticals’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Verrica Pharmaceuticals is more favorable than GSK.

Summary

GSK beats Verrica Pharmaceuticals on 8 of the 13 factors compared between the two stocks.

About Verrica Pharmaceuticals

(Get Free Report)

Verrica Pharmaceuticals is a dermatology-focused biopharmaceutical company that develops and commercializes treatments for skin diseases. The company is based in West Chester, Pennsylvania, and its activities include both marketed products and investigational therapies. Its FDA-approved product, YCANTH, is a topical cantharidin treatment for molluscum contagiosum in adults and children ages 2 and older. The treatment is applied by a healthcare professional. Verrica is also developing therapies for other skin conditions.

About GSK

(Get Free Report)

GSK plc is a global biopharmaceutical company headquartered in the United Kingdom. It researches, develops and manufactures medicines and vaccines, with a focus on areas including infectious diseases, HIV, respiratory and immune conditions, and cancer. Its products include vaccines such as Shingrix, which helps prevent shingles, and Arexvy, for respiratory syncytial virus (RSV). GSK also makes specialty medicines, including treatments for HIV and respiratory diseases, and continues to develop new medicines and vaccines through its research programs.

Receive News & Ratings for Verrica Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verrica Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.